UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth

The UK prescription pharmaceutical market was valued at $18.1 billion in 2009. Key growth drivers include growing use of chronic high-value innovative treatments driven by a rising elderly population, high public healthcare expenditure as proportion of total healthcare expenditure, relatively light pricing controls through the PPRS, and speedy domestic drug approvals.

Pharmaceutical Company Outlook to 2014

PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from 2002-08. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not all sectors are equally exposed, prompting a shake-up of the industry and an increasing pursuit of cost savings to sustain operating profit growth rates.

Multiple Sclerosis - Next generation therapies signal the start of a new era

With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (2009/2019).

Trends in Generics Industry Ownership: Evaluating changing industry paradigms and emerging players

Startups & other generic drug companies are attempting to expand, seeking capital in China, Latin America & other regions are privatizing. This report examines these ownership structures in the context of current & future industry trends, discussing current best practices through nine case studies & examining which ownership structures are most effective for which types of situations.

Innovations and Opportunities in Therapeutic Vaccines: Technology platforms, key players, and early pipeline candidates

This report explains what therapeutic vaccines are, how they work, and why drug developers around the world are using this approach to address everything from allergies to literally every kind of cancer. More than 70 new proprietary technologies are named and explained, with details of licensing deals and intellectual property positions.

The Cardiovascular Market Outlook to 2015:Competitive landscape, global market analysis, key trends and pipeline analysis

This report provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players.

The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts

This report provides a comprehensive analysis of key vaccine classes and leading companies within the global vaccines market. Leading brands for each major indication within both adult and pediatric population segments are assessed to identify key growth areas and leading products through to 2014. This report reviews the factors and underlying trends that are currently shaping market development.

The Impact of Authorized Generic Pharmaceuticals on the Introduction of Other Generic Pharmaceuticals

This study examines the impact of authorized generic drugs on the introduction of other generic pharmaceuticals, and therefore on the potential benefits of generic drugs for U.S. consumers. The analysis focuses on the incentives and disincentives of generic companies to challenge the patents of brand products, in order to qualify for a special, 180-day period of market exclusivity, when their generic product still faces potential competition in that period from generics authorized by the original developer.

Full 16 pages Report is available for download at Repository.

Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017

GlobalData, the industry analysis specialist, has released a new report, "Type 1 Diabetes - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global type 1 diabetes sector.

Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest report, "Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016 " which provides the key data, information and analysis on the Parkinson's disease (PD) market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with Parkinson's disease, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the Parkinson's disease market.

Pulmonary Arterial Hypertension (PAH) - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest research, "Pulmonary Arterial Hypertension (PAH) - Pipeline Analysis and Market Forecasts to 2016", which provides key data, information and analysis on the PAH market. The report provides a comprehensive overview of the annualized market data from 2005 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs, competitive assessments, the product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition, and the key players of the PAH market.

Dyslipidemia - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist's new report, "Dyslipidemia - Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dyslipidemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

HIV-AIDS - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest report, "HIV-AIDS - Pipeline Assessment and Market Forecasts to 2016" which provides the key data, information and analysis on the HIV/AIDS market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with HIV/AIDS, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the HIV/AIDS market.

Biomarkers in Late-Stage Clinical Trials: Applications, opportunities and activities of leading players

Biomarkers reduce the attrition rate of late-stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of clinical trials, and help researchers complete the drug development process at a faster pace.

Depression - Generic induced brand erosion leads to market decline

The depression market was valued at around $11.04 billion in 2007 across the seven major markets. Following marginal growth to 2011 ($12.01 billion), the market is forecast to decline in value through to 2017 ($9.81 billion) when brand erosion due to generic incursion affecting all major drug classes used to treat depression finally outweighs the success of reformulations and follow-on products.

Antidepressants - Novel mechanism offers hope in depressed market

With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial potential and the most promising candidate to date is Servier and Novartis's melatonin agonist and serotonin antagonist Valdoxan (agomelatine).

The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities

Since 2000, oncology has become one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents. Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.

Innovation and market growth opportunities in bone metastases and emerging supportive care challenges

Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.